NICE

UK health technology assessment body evaluating clinical and cost-effectiveness of treatments for NHS adoption.

NICE

Apr 6, 2026

•

5 min read

NICE Conference 2026: What Was Said, What It Means, and Whether to Be Optimistic

A new chief exec, a QALY debate that won't go away, and the moment NICE and the MHRA finally got in the same room.

Mirko von Hein

Market Access

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

Feb 16, 2026

•

6 min read

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The UK spends significantly less of its health budget on branded medicines than comparable nations. Termination rates in the appraisal process have doubled. And companies are increasingly choosing not to launch here at all. A conversation with the ABPI's Jack Neill-Hall about what's at stake—and where the opportunity lies.

Mirko von Hein

Pharmaceutical Policy

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

Feb 8, 2026

•

7 min read

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

The Warning That Went Unheeded

Mirko von Hein

NICE

NICE Conference 2026: What Was Said, What It Means, and Whether to Be Optimistic

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

The HEOR Intel You Actually Need

Tracking what matters in HEOR, market access, and pharma consulting for your career success